AUTL Autolus Therapeutics ADS

Autolus Therapeutics announces participation in upcoming conferences

Autolus Therapeutics announces participation in upcoming conferences

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November.

Truist Securities BioPharma Symposium

Panel: Considerations for an Oncology Company’s Autoimmune Side Hustle

Date and time: 9 November 2023, 11:40am ET / 16:40pm GMT

Location: New York, USA

Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Jefferies London Healthcare Conference  

Fireside Chat

Date and time: 16 November 2023, 4:00am ET / 9:00am GMT

Location: London, UK

Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Piper Sandler 35th Annual Healthcare Conference

Fireside Chat

Date and time: 28 November 2023, 11:30am ET/ 16:30pm GMT

Location: New York, USA

Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Find out more information about upcoming events and any webcast and replay details at:

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit

Contact:

Julia Wilson

+44 (0) 7818 430877

Susan A. Noonan

S.A. Noonan Communications



Lauren Williams

Investase

0

 



EN
06/11/2023

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE ...

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after infusion, suggesting an immune resetNine patients were evaluable for safety, no ICANS or high-grade CRS were observed LONDON and GAITHERSBURG, Md., Dec. 08, 2025 (GLOBE NE...

December 8, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B...

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel’s adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T persistence at three months as pote...

December 8, 2025 1 EN
Guy Sips ... (+3)
  • Guy Sips
  • Jacob Mekhael
  • Wim Lewi
JEN JENSEN-GROUP
MONT MONTEA SCA
AUTL AUTOLUS THERAPEUTICS ADS
BTLS BIOTALYS NV
12/02/25 December 2, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company’s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus’ Board. “Autolus has entered a new pha...

December 1, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus NICE recommends Aucatzyl for r/r adult B-ALL in England and Wa...

Autolus announced that the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending Aucatzyl (obe-cel, CD19 CAR-T) for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (=26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL). Aucatzyl will be available through routine commissioning by the NHS, and Autolus intends to launch the product in England and Wales immi...

AUTL AUTOLUS THERAPEUTICS ADS
11/26/25 November 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch